Tectonic Therapeutic (TECX) Income towards Parent Company (2017 - 2026)
Tectonic Therapeutic's (TECX) quarterly Income towards Parent Company came in at -$53.8 million in Q1 2026, down 236.16% year-on-year from $39.5 million in Q1 2025, and down 179.85% on a QoQ basis from -$19.2 million in Q4 2025.
Tectonic Therapeutic (TECX) Income towards Parent Company (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has 10 years of Income towards Parent Company data on file, last reported at -$53.8 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 236.16% year-over-year to -$53.8 million in Q1 2026; TTM through Mar 2026 was -$112.0 million, a 99.14% decrease from a year earlier, with the FY2025 full-year figure at -$74.2 million, down 33.65% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$53.8 million, down from -$19.2 million in the prior quarter.
- Over the last five years, Income towards Parent Company for TECX reached as high as -$9.3 million in Q4 2023 and fell as low as -$53.8 million in Q1 2026.
- Historically, Income towards Parent Company has averaged -$20.5 million across 5 years, with a median of -$19.0 million in 2025.
- Across the five-year window, Income towards Parent Company surged 63.69% in 2023 and slumped 236.16% in 2026, its largest moves.
- Year by year, Income towards Parent Company stood at -$25.5 million in 2022, then jumped by 63.68% to -$9.3 million in 2023, then fell by 6.46% to -$9.9 million in 2024, then plunged by 94.71% to -$19.2 million in 2025, then plunged by 179.85% to -$53.8 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$53.8 million in Q1 2026, -$19.2 million in Q4 2025, and -$19.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn |
| 10 | Tectonic Therapeutic | 577.71 Mn | 577.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.80 Mn |
| Dec 31, 2025 | -19.23 Mn |
| Sep 30, 2025 | -19.04 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Mar 31, 2025 | -16.01 Mn |
| Dec 31, 2024 | -9.87 Mn |
| Sep 30, 2024 | -17.72 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -13.23 Mn |
| Dec 31, 2023 | -9.28 Mn |
| Sep 30, 2023 | -11.09 Mn |
| Jun 30, 2023 | -10.64 Mn |
| Mar 31, 2023 | -25.97 Mn |
| Dec 31, 2022 | -25.54 Mn |
| Sep 30, 2022 | -24.02 Mn |
| Jun 30, 2022 | -29.31 Mn |
| Mar 31, 2022 | -31.12 Mn |
| Dec 31, 2021 | -28.31 Mn |
| Sep 30, 2021 | -32.62 Mn |
| Jun 30, 2021 | -37.34 Mn |